
GLP-1 Drugs Linked to Lower Mental Illness Risk and Mortality in New Studies
New research indicates that GLP-1 receptor agonists, widely used for weight loss and diabetes, may offer significant psychiatric and cardiovascular benefits. A genetic study suggests these drugs reduce the risk of depression and bipolar disorder independent of weight loss, while a large observational study links their use to a 24% lower mortality rate in patients with serious mental illness. Although prescribing rates for these medications have risen among adults with mental health conditions, disparities remain for those with schizophrenia.













